

Test Requisition Form





TEST NAME: HelioLiver Test (FT-TP01425) **ORDERING PROVIDER** FULGENT CLIENT ID*: PROVIDER LAST NAME* PROVIDER FIRST NAME **PATIENT** LAST NAME* FIRST NAME* NPI* PHONE* DATE OF BIRTH (MM/DD/YYYY)* GENETIC SEX EMAIL* O Male O Female O Unknown MED REC#/PATIENT IDENTIFIER* PHONE INSTITUTION/PRACTICE NAME FMAII INSTITUTION ADDRESS STATE/PROVINCE POSTAL CODE COUNTRY I give permission to Fulgent Genetics to perform testing as described. By opting in below, I also give permission for his or her specimen and clinical information to be used in de-identified PRIMARY CONTACT NAME PRIMARY CONTACT PHONE/EMAIL research at Fulgent and for publication, if appropriate. The patient's name or other personal identifying information will not be used in or linked to the results of any studies and publications. More information is available at www.fulgentgenetics.com/policies/privacy-policy. I attest that I have fully informed the patient about the purpose, capabilities, and limitations By signing, I authorize Fulgent Genetics/Inform Diagnostics to contact me directly, and use the of the ordered test. The patient has voluntarily given his or her full consent for the ordered test provided billing instructions to bill the indicated method and release medical information and a signed copy of this consent is available on file. concerning the test to the assigned insurance company (if applicable). STATEMENT OF MEDICAL NECESSITY By signing below, I, the ordering Medical Provider, confirm that testing is medically necessary Check this box if you are a New York state resident and give permission for Fulgent to and that test results may impact medical management for the patient. retain any remaining sample longer than 60 days after the completion of testing X PATIENT SIGNATURE (REQUIRED FOR BILLING) DATE (MM/DD/YYYY) ORDERING PROVIDER SIGNATURE (REQUIRED) DATE (MM/DD/YYYY) SPECIMEN DETAILS Please collect the following specimens for the patient: • Whole Blood: 2 x 10mL PAXgene Blood ccfDNA • Serum: 1 x 7.5mL BD Vacutainer SST Tube SAMPLE COLLECTION DATE*: (MM/DD/YYYY) *Required Field BILLING INFORMATION Select one billing option and complete all information required in order to prevent a delay in the release of test results OPTION 1: Patient Self-Pay OR OPTION 2: Institutional Billing FULGENT BILLING ID*: INSTITUTION/PAYOR FIRST & LAST NAME ATTENTION TO ADDRESS STATE/PROVINCE POSTAL CODE COUNTRY PHONE FAX OPTION 3: Insurance Billing Please attach front and back of all insurance cards, ABN, medical criteria form. ICD-10 CODE(S)* (PLEASE PRINT LEGIBLY AND ENTER ALL THAT APPLY) REFERRAL/PRIOR AUTH PRIMARY INSURANCE ID INSURANCE NAME GROUP INSURANCE PHONE # STATE INSURANCE PLAN NAME OF INSURED RELATION TO PATIENT DATE OF BIRTH (MM/DD/YYYY) SECONDARY INSURANCE ID INSURANCE PHONE # INSURANCE NAME GROUP INSURANCE PLAN NAME OF INSURED RELATION TO PATIENT DATE OF BIRTH (MM/DD/YYYY) ICD-10 code(s) are required for laboratory services. The patient's medical record must support the diagnosis code(s) indicated by the physician. The information below has been **ICD-10 CODES** nience and reference only. Fulgent/Inform Diagnostics makes no recommendation on the use of diagnosis code(s). Liver Disease – K70.31 with ascites K74 Fibrosis and cirrhosis of liver – K74.5 Biliary cirrhosis, K76 Other diseases of liver – B18.0 Chronic viral hepatitis B – K70.4 Alcoholic hepatic failure – K70.40 without coma – K74.0 Hepatic fibrosis – K74.00 unspecified unspecified K74.6 Other and unspecified (Includes NAFLD but excludes NASH) with delta-agent B18.1 Chronic viral hepatitis B K70 Alcoholic liver disease K70.0 Alcoholic fatty liver - K70.1 Alcoholic hepatitis - K70.41 with coma - K74.01 early fibrosis cirrhosis of liver K77 Liver disorders in diseases

- K70.10 without ascites - K70.11 with ascites
- K70.2 Alcoholic fibrosis and sclerosis of liver
- K70.3 Alcoholic cirrhosis of
- K70.30 without ascites
- K70.9 Alcoholic liver disease, unspecified
- K71 Toxic liver disease K72 Hepatic failure, not
- elsewhere classified K73 Chronic hepatitis, not elsewhere classified
- K74.02 .. advanced fibrosis
- K74.1 Hepatic sclerosis
- K74.2 Hepatic fibrosis with hepatic sclerosis
- K74.3 Primary biliary cirrhosis - K74.4 Secondary biliary
- cirrhosis
- K74.60 Unspecified cirrhosis of
- K74.69 Other cirrhosis of liver K75 Other inflammatory liver diseases
- K75.81 Nonalcoholic steatohepatitis (NASH)
- classified elsewhere

Viral Hepatitis

B15 Acute hepatitis A B16 Acute hepatitis B B17 Other acute viral hepatitis B18 Chronic viral hepatitis

- without delta-agent

 B18.2 Chronic viral hepatitis C

 B18.8 Other chronic viral
- hepatitis B18.9 Chronic viral hepatitis,
- unspecified B19 Unspecified viral hepatitis



All Fields Required

Certificate of Medical Necessity





The HelioLiver[™] test is a multi-analyte blood test that can detect the presence of hepatocellular carcinoma with an algorithm that evaluates DNA methylation patterns and protein tumor markers. It is intended to be used as surveillance for patients who are high-risk for liver cancer due to underlying chronic liver disease.

PATIENT INFORMA	ATION	PR	PROVIDER INFORMATION					
NAME		ORD	ORDERING PHYSICIAN NAME NPI					
DATE OF BIRTH (MM/DD/YYYY)		NPI						
INSURANCE PAYER		OFFI	ICE ADDRESS					
INSURANCE ID		CITY	,	STAT	E/PROVINCE	POSTAL CODE	COUNTRY	
		OFFI	ICE PHONE		OFFICE	FAX		
MEDICAL NOTES								
CPT CODE 81479		DATE	DATE OF SPECIMEN COLLECTION (MM/DD/YYYY)					
ICD-10 CODE(S)								
SYMPTOMS / CLINICAL FINDING	5S							
☐ Cirrhosis	☐ Hepatitis B ☐ N	NAFLD] NASH	☐ Fatty Live	er Disease			
Other (Please List):								
PRIOR HISTORY (CHECK ALL THA	AT APPLY)							
☐ Hepatitis B (HBV)	☐ Hepatitis C (HCV)	☐ Alcohol	☐ Ge	enetic Disorders	5			
to have higher sensitive curative options such a stage chemotherapy to this test has not been tics. Testing in Laborate	ommend the surveillance of high- ity when detecting lesions in the l as surgery and ablation are avail reatment. FDA cleared or approved. This te ories Certified to Perform High Context of the patient's medical history	iver than currently availe able. In addition to impress st has been validated in amplexity Testing under t	able blood tes oving outcome accordance v CLIA). Test res	sts, catching HC es, these option vith the FDA's G	C in early as are mor uidance D	stages where e cost-effectiv ocument (Poli	potentially e than later cy for Diagnos-	
X		X						
ORDERING PROVIDER NAME (REQUIRED)		ORDERING PROVIDER SIGN	ORDERING PROVIDER SIGNATURE (REQUIRED)				YYY)	